{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:51:13Z","timestamp":1777517473090,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T00:00:00Z","timestamp":1518998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s10354-018-0623-5","type":"journal-article","created":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T10:26:49Z","timestamp":1519036009000},"page":"159-167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Methadone as anticancer treatment: hype, hope, or hazard?","Methadon als Antitumortherapie: Schwindel, Hoffnung oder Risiko?"],"prefix":"10.1007","volume":"168","author":[{"given":"Gudrun","family":"Kreye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva-Katharina","family":"Masel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Hackner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Stich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedemann","family":"Nauck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,19]]},"reference":[{"issue":"2","key":"623_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1056\/NEJM198507113130205","volume":"313","author":"KM Foley","year":"1985","unstructured":"Foley KM. The treatment of cancer pain. N\u00a0Engl J Med. 1985;313(2):84\u201395.","journal-title":"N Engl J Med"},{"issue":"5","key":"623_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1054\/bjoc.2001.1680","volume":"84","author":"GW Hanks","year":"2001","unstructured":"Hanks GW, Conno F, et\u00a0al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84(5):587\u201393.","journal-title":"Br J Cancer"},{"key":"623_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s004820100104","volume":"16","author":"L Radbruch","year":"2002","unstructured":"Radbruch L, Nauck F. Morphin und andere Opioide in der Tumorschmerztherapie. Die Empfehlungen der EAPC. Schmerz. 2002;16:186\u201393.","journal-title":"Schmerz"},{"issue":"9","key":"623_CR4","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1200\/JCO.2001.19.9.2542","volume":"19","author":"N Cherny","year":"2001","unstructured":"Cherny N, Ripamonti C, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J\u00a0Clin Oncol. 2001;19(9):2542\u201354.","journal-title":"J Clin Oncol"},{"issue":"5","key":"623_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1526-4637.2008.00461.x","volume":"9","author":"DJ Weschules","year":"2008","unstructured":"Weschules DJ, et\u00a0al. Pain Med. 2008;9(5):595\u2013612.","journal-title":"Pain Med"},{"issue":"7","key":"623_CR6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO;2-0","volume":"76","author":"NJ Cherny","year":"1995","unstructured":"Cherny NJ, Chang V, et\u00a0al. Opioid pharmacotherapy in the management of cancer pain: a\u00a0survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995;76(7):1283\u201393.","journal-title":"Cancer"},{"key":"623_CR7","volume-title":"WHO model list of essential medicines","author":"World Health Organization","year":"2007","unstructured":"World Health Organization. WHO model list of essential medicines. 15th\u00a0ed. 2007. http:\/\/www.who.int\/medicines\/publications\/08_ENGLISH_indexFINAL_EML15.pdf .","edition":"15"},{"key":"623_CR8","volume-title":"Arzneistoffe","author":"HJ Roth","year":"2000","unstructured":"Roth HJ. Arzneistoffe. Stuttgart: Deutscher Apotheker Verlag; 2000."},{"issue":"2","key":"623_CR9","doi-asserted-by":"publisher","first-page":"PL45","DOI":"10.1016\/0024-3205(94)00937-6","volume":"56","author":"K Kristensen","year":"1995","unstructured":"Kristensen K, Christensen CB, et\u00a0al. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 1995;56(2):PL45\u2013PL50.","journal-title":"Life Sci"},{"issue":"2","key":"623_CR10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0026-895X(25)09932-8","volume":"45","author":"K Raynor","year":"1994","unstructured":"Raynor K, Kong H, et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994;45(2):330\u20134.","journal-title":"Mol Pharmacol"},{"issue":"3","key":"623_CR11","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0022-3565(25)10630-7","volume":"274","author":"EE Codd","year":"1995","unstructured":"Codd EE, Shank RP, et\u00a0al. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J\u00a0Pharmacol Exp Ther. 1995;274(3):1263\u201370.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"623_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1046\/j.1365-2125.1999.00974.x","volume":"48","author":"A Rostami-Hodjegan","year":"1999","unstructured":"Rostami-Hodjegan A, Wolff K, et al. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol. 1999;48(1):43\u201352.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"623_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2165\/00003088-198611020-00001","volume":"11","author":"J Sawe","year":"1986","unstructured":"Sawe J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet. 1986;11(2):87\u2013106.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"623_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","volume":"84","author":"HS Smith","year":"2009","unstructured":"Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613\u201324.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"623_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0304-3959(93)90125-9","volume":"52","author":"R Fainsinger","year":"1993","unstructured":"Fainsinger R, Schoeller T, et\u00a0al. Methadone in the management of cancer pain: a\u00a0review. Pain. 1993;52(2):137\u201347.","journal-title":"Pain"},{"issue":"3","key":"623_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1526-4637.2006.00289.x","volume":"9","author":"DJ Weschules","year":"2008","unstructured":"Weschules DJ, et\u00a0al. Actual and potential drug interactions associated with methadone. Pain Med. 2008;9(3):315\u201344.","journal-title":"Pain Med"},{"issue":"14","key":"623_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2165\/00003088-200443140-00003","volume":"43","author":"J Lotsch","year":"2004","unstructured":"Lotsch J, Skarke C, et\u00a0al. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet. 2004;43(14):983\u20131013.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"623_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.clpt.2005.09.010","volume":"79","author":"J Lotsch","year":"2006","unstructured":"Lotsch J, Skarke C, et\u00a0al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther. 2006;79(1):72\u201389.","journal-title":"Clin Pharmacol Ther"},{"key":"623_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003971.pub31","author":"AB Nicholson","year":"2017","unstructured":"Nicholson AB, et\u00a0al. Methadone for cancer pain. Cochrane Database Syst Rev. 2017; 2. https:\/\/doi.org\/10.1002\/14651858.CD003971.pub31 .","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"623_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1526-4637.2008.00461.x","volume":"9","author":"DJ Weschules","year":"2008","unstructured":"Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med. 2008;9(5):595\u2013612.","journal-title":"Pain Med"},{"issue":"3","key":"623_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/104990910101800312","volume":"18","author":"F Nauck","year":"2001","unstructured":"Nauck F, Ostgathe C, et\u00a0al. A German model for methadone conversion. Am J Hosp Palliat Care. 2001;18(3):200\u20132.","journal-title":"Am J Hosp Palliat Care"},{"key":"623_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00482-016-0183-9","volume":"31","author":"H Hofbauer","year":"2017","unstructured":"Hofbauer H, Schenk M, et\u00a0al. Schmerz. 2017;31:2\u20134.","journal-title":"Schmerz"},{"key":"623_CR23","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.4161\/cc.28493","volume":"13","author":"C Friesen","year":"2014","unstructured":"Friesen C, Hormann I, et al. Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma. Cell Cycle. 2014;13:1560\u201370.","journal-title":"Cell Cycle"},{"issue":"5","key":"623_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.18632\/oncotarget.952","volume":"4","author":"C Friesen","year":"2013","unstructured":"Friesen C, Roscher M, et\u00a0al. Cell death sensitization of leukemia cells by opioid receptor activation. Oncotarget. 2013;4(5):677\u201390.","journal-title":"Oncotarget"},{"key":"623_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.phrs.2015.03.017","volume":"95\u201396","author":"A Bundscherer","year":"2015","unstructured":"Bundscherer A, Malsy M, et\u00a0al. Effects of ropivacaine, bupivacaine and sufentanil in colon and pancreatic cancer cells in vitro. Pharmacol Res. 2015;95\u201396:126\u201331.","journal-title":"Pharmacol Res"},{"issue":"1\u20132","key":"623_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0304-3835(02)00360-9","volume":"187","author":"Y Harimaya","year":"2002","unstructured":"Harimaya Y, Koizumi K, et al. Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett. 2002;187(1\u20132):121\u20137.","journal-title":"Cancer Lett"},{"key":"623_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12871-015-0076-y","volume":"15","author":"M Malsy","year":"2015","unstructured":"Malsy M, Gebhardt K, et al. Effects of ketamine, s\u2011ketamine, and MK 801 on proliferation, apoptosis, and necrosis in pancreatic cancer cells. BMC Anesth. 2015;15:111.","journal-title":"BMC Anesth"},{"key":"623_CR28","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1097\/00000539-200006000-00028","volume":"90","author":"P Sacerdote","year":"2000","unstructured":"Sacerdote P, Bianchi M, et\u00a0al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg. 2000;90:1411\u20134.","journal-title":"Anesth Analg"},{"key":"623_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000078444","volume":"1","author":"Y Shavit","year":"2004","unstructured":"Shavit Y, Ben-Eliyahu S, et al. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation. 2004;1:255\u201360.","journal-title":"Neuroimmunomodulation"},{"key":"623_CR30","first-page":"1846","volume":"63","author":"I Tegeder","year":"2003","unstructured":"Tegeder I, Grosch S, et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res. 2003;63:1846\u201352.","journal-title":"Cancer Res"},{"issue":"3","key":"623_CR31","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.21873\/anticanres.11438","volume":"37","author":"C Onken","year":"2017","unstructured":"Onken C, Friesen C, et al. Safety and tolerance of D.L-methadone in combination with chemotherapy in patients with glioma. Anticancer Res. 2017;37(3):1227\u201336.","journal-title":"Anticancer Res"},{"issue":"6","key":"623_CR32","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1089\/jpm.2012.0612","volume":"16","author":"SR Salpeter","year":"2013","unstructured":"Salpeter SR, Buckley JS, et al. The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia. J\u00a0Pall Med. 2013;16(6):616\u201322.","journal-title":"J Pall Med"},{"key":"623_CR33","first-page":"577","volume":"14","author":"S Alinejad","year":"2015","unstructured":"Alinejad S, Kazemi T, et\u00a0al. A systematic review of the cardiotoxicity of methadone. EXCLI J. 2015;14:577\u2013600.","journal-title":"EXCLI J."},{"key":"623_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5055\/jom.2016.0325","volume":"12","author":"DL Anghelescu","year":"2016","unstructured":"Anghelescu DL, Patel RM, et al. Methadone prolongs cardiac conduction in young patients with cancer-related pain. J\u00a0Opioid Manag. 2016;12:131\u20138.","journal-title":"J Opioid Manag"},{"key":"623_CR35","first-page":"948","volume":"20","author":"HS Minkowitz","year":"2014","unstructured":"Minkowitz HS, Scranton R, et al. Development and validation of a\u00a0risk score to identify patients at high risk for opioid-related adverse drug events. J\u00a0Manag Care Spec Pharm. 2014;20:948\u201358.","journal-title":"J Manag Care Spec Pharm"},{"key":"623_CR36","volume-title":"\u00dcber Struktur und Vielfalt im \u00f6ffentlichen Recht","author":"K Christian","year":"2008","unstructured":"Christian K. Off-label use\u201d von Arzneimitteln. In: Enn\u00f6ckl D, Raschauer N, et al., editors. \u00dcber Struktur und Vielfalt im \u00f6ffentlichen Recht. Vienna: Springer; 2008."},{"key":"623_CR37","unstructured":"http:\/\/www.dgn.org\/presse\/pressemitteilungen\/3040-gliomtherapie-mit-methadon-bishernur-experimentell-getestet-wirkung-eimmenschen-voellig-unklar . Accessed 29 Oct 2017."},{"key":"623_CR38","unstructured":"http:\/\/www.oegho.at\/online-services\/news\/news-detail-startseite\/artikel\/stellungnahme-methadon-bei-krebspatienten.html . Accessed 29 Oct 2017."},{"key":"623_CR39","unstructured":"http:\/\/www.oesg.at\/index.php?eID=dumpFile&t=f&f=557&token=fece2a2a1f2e1e05304da85e0d96ef7637488690 . Accessed 29 Oct 2017."},{"issue":"9","key":"623_CR40","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1007\/s00520-011-1320-8","volume":"20","author":"C Ostgathe","year":"2012","unstructured":"Ostgathe C, et al. Practicability, safety, and efficacy of a\u00a0\u201cGerman model\u201d for opioid conversion to oral levo-methadone. Support Care Cancer. 2012;20(9):2105\u201310. https:\/\/doi.org\/10.1007\/s00520-011-1320-8 .","journal-title":"Support Care Cancer"},{"issue":"2","key":"623_CR41","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jpainsymman.2015.02.029","volume":"50","author":"S McLean","year":"2015","unstructured":"McLean S, Tworney F. Methods of rotation from another strong opioid to methadone for the management of cancer pain: a\u00a0systematic review of the available evidence. J\u00a0Pain Symptom Manage. 2015;50(2):248\u201359. https:\/\/doi.org\/10.1016\/j.jpainsymman.2015.02.029 .","journal-title":"J. Pain. Symptom Manage."},{"key":"623_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12920","author":"A Rennick","year":"2015","unstructured":"Rennick A, et\u00a0al. Variability in opioid equivalence calculations. Pain Med. 2015; https:\/\/doi.org\/10.1111\/pme.12920 .","journal-title":"Pain Med"},{"key":"623_CR43","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2017.0157","author":"P F\u00fcrst","year":"2017","unstructured":"F\u00fcrst P, et al. Improved pain control in terminally ill cancer patients by introducing low-dose oral methadone in addition to ongoing opioid treatment. J\u00a0Palliat Med. 2017; https:\/\/doi.org\/10.1089\/jpm.2017.0157 .","journal-title":"J Palliat Med"},{"key":"623_CR44","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.pain.2011.03.023","volume":"152","author":"EE Krebs","year":"2011","unstructured":"Krebs EE, Becker WC, et al. Comparative mortality among department of veterans affairs patients prescribed methadone or long-acting morphine for chronic pain. Pain. 2011;152:1789\u201395.","journal-title":"Pain"},{"issue":"6","key":"623_CR45","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1089\/jpm.2016.0316","volume":"20","author":"A Reddy","year":"2017","unstructured":"Reddy A, et\u00a0al. Overall survival among cancer patients undergoing opioid rotation to methadone compared to other opioids. J\u00a0Palliat Med. 2017;20(6):656\u201361.","journal-title":"J Palliat Med"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-018-0623-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-018-0623-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-018-0623-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:20:10Z","timestamp":1751408410000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-018-0623-5"}},"subtitle":["A series of case reports and a\u00a0short review of the current literature and recommendations of the societies","Eine Serie von Kasuistiken und kurzer \u00dcberblick \u00fcber aktuelle Literatur sowie Empfehlungen der Fachgesellschaften"],"short-title":[],"issued":{"date-parts":[[2018,2,19]]},"references-count":45,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["623"],"URL":"https:\/\/doi.org\/10.1007\/s10354-018-0623-5","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,19]]},"assertion":[{"value":"1 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.\u00a0Kreye, E.-K.\u00a0Masel, K.\u00a0Hackner, B.\u00a0Stich, and F.\u00a0Nauck declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}